NO20041003L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20041003L
NO20041003L NO20041003A NO20041003A NO20041003L NO 20041003 L NO20041003 L NO 20041003L NO 20041003 A NO20041003 A NO 20041003A NO 20041003 A NO20041003 A NO 20041003A NO 20041003 L NO20041003 L NO 20041003L
Authority
NO
Norway
Prior art keywords
new connections
connections
new
Prior art date
Application number
NO20041003A
Other languages
English (en)
Other versions
NO327009B1 (no
Inventor
Paul Adrian Wyman
Mervyn Thompson
Harshad Kantilal Rami
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0122156A external-priority patent/GB0122156D0/en
Priority claimed from GB0130503A external-priority patent/GB0130503D0/en
Priority claimed from GB0130505A external-priority patent/GB0130505D0/en
Priority claimed from GB0130547A external-priority patent/GB0130547D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20041003L publication Critical patent/NO20041003L/no
Publication of NO327009B1 publication Critical patent/NO327009B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
NO20041003A 2001-09-13 2004-03-10 Nye forbindelser, fremgangsmate for fremstilling derav, anvendelse av forbindelsen samt farmasoytisk preparat omfattende denne NO327009B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0122156A GB0122156D0 (en) 2001-09-13 2001-09-13 Novel compounds
GB0130503A GB0130503D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130505A GB0130505D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130547A GB0130547D0 (en) 2001-12-20 2001-12-20 Novel compounds
PCT/GB2002/004206 WO2003022809A2 (en) 2001-09-13 2002-09-13 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain

Publications (2)

Publication Number Publication Date
NO20041003L true NO20041003L (no) 2004-06-04
NO327009B1 NO327009B1 (no) 2009-04-06

Family

ID=27447989

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20041003A NO327009B1 (no) 2001-09-13 2004-03-10 Nye forbindelser, fremgangsmate for fremstilling derav, anvendelse av forbindelsen samt farmasoytisk preparat omfattende denne
NO20085077A NO20085077L (no) 2001-09-13 2008-12-04 Nye forbindelser
NO20085078A NO20085078L (no) 2001-09-13 2008-12-04 Nye forbindelser

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20085077A NO20085077L (no) 2001-09-13 2008-12-04 Nye forbindelser
NO20085078A NO20085078L (no) 2001-09-13 2008-12-04 Nye forbindelser

Country Status (31)

Country Link
US (1) US8063078B2 (no)
EP (3) EP1425277B8 (no)
JP (2) JP4463552B2 (no)
KR (3) KR101063679B1 (no)
CN (1) CN1247568C (no)
AP (1) AP1818A (no)
AR (1) AR038786A1 (no)
AT (1) ATE420083T1 (no)
AU (1) AU2002329397B2 (no)
BR (1) BR0212468A (no)
CA (1) CA2458632C (no)
CY (1) CY1109449T1 (no)
DE (1) DE60230773D1 (no)
DK (1) DK1425277T3 (no)
EA (1) EA007731B1 (no)
ES (1) ES2316607T3 (no)
HU (1) HUP0401923A3 (no)
IL (2) IL160755A0 (no)
MA (1) MA26216A1 (no)
MX (1) MXPA04002379A (no)
MY (1) MY138086A (no)
NO (3) NO327009B1 (no)
NZ (1) NZ531137A (no)
OA (1) OA12659A (no)
PE (1) PE20030417A1 (no)
PL (1) PL213639B1 (no)
PT (1) PT1425277E (no)
SI (1) SI1425277T1 (no)
TW (1) TWI283665B (no)
UY (1) UY27446A1 (no)
WO (1) WO2003022809A2 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030417A1 (es) * 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
EP2033951A3 (en) 2002-02-01 2009-12-23 Euro-Celtique S.A. 2-Piperazine-pyridines useful for treating pain
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
IL165862A0 (en) 2002-06-28 2006-01-15 Euro Celtique Sa Therapeutic piperazine derivatives useful for tre ating pain
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0221157D0 (en) * 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
AU2003270199A1 (en) * 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
DK1569896T3 (da) 2002-12-06 2007-12-10 Xention Ltd Tetrahydronaphthalenderivater
GB0229808D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2004078749A1 (en) * 2003-03-06 2004-09-16 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
US7514562B2 (en) 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0305426D0 (en) * 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
US7615557B2 (en) 2003-10-01 2009-11-10 Xention Limited Tetrahydro-naphthalene and urea derivatives
JP4935073B2 (ja) 2003-10-14 2012-05-23 味の素株式会社 エーテル誘導体
US20080045546A1 (en) * 2003-10-15 2008-02-21 Axel Bouchon Tetradydro-Naphthalene And Urea Derivatives
EP1685112B1 (en) 2003-11-08 2011-07-20 Bayer Schering Pharma Aktiengesellschaft Tetrahydro-quinolinylurea derivatives as vr1 antagonists
WO2005095327A1 (ja) * 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
CA2584502A1 (en) 2004-06-24 2006-01-05 Incyte Corporation 2-methylpropanamides and their use as pharmaceuticals
JP2008508190A (ja) 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
EP1889830A1 (en) * 2006-07-10 2008-02-20 Pharmeste S.r.l. Biarylcarboxyarylamides as vanilloid-1 receptor modulators
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
CA2658925C (en) * 2006-07-27 2015-07-14 Amorepacific Corporation Novel sulfonylamino acrylamide derivatives, isomer thereof,or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
CN101541758A (zh) 2006-08-25 2009-09-23 艾博特公司 抑制trpv1的吲唑衍生物及其用途
WO2008079683A2 (en) 2006-12-20 2008-07-03 Abbott Laboratories N- (5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
CN102036969A (zh) 2008-03-20 2011-04-27 雅培制药有限公司 制造作为trpv1拮抗剂的中枢神经系统药剂的方法
US8362012B2 (en) 2008-04-18 2013-01-29 Daewoong Pharmaceutical Co., Ltd. Benzoxazine benzimidazole derivative, a pharmaceutical composition comprising the same, and a use thereof
ES2433008T3 (es) * 2008-05-07 2013-12-05 Dainippon Sumitomo Pharma Co., Ltd. Derivado de éster de ácido amino-1-carboxílico cíclico y composición farmacéutica que contiene el mismo
WO2010026128A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited N-(3-methyl-5-isoquinolinyl)-n'-((3r)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl) urea for the treatment of rhinitis
WO2010026129A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited The trpvl antagonist sb-705498 for treating rhinitis
JP2013028536A (ja) * 2009-11-11 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物
WO2012045729A1 (en) 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
GB201101517D0 (en) * 2011-01-28 2011-03-16 Proximagen Ltd Receptor antagonists
US8754101B2 (en) 2011-04-11 2014-06-17 Glaxo Group Limited N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424760A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424761A (en) 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
ATE113205T1 (de) 1988-06-17 1994-11-15 Procter & Gamble Anwendung von vanillin-derivaten zur herstellung eines arzneimittels zur behandlung von herpes simplex-infektion.
HU206082B (en) 1988-12-23 1992-08-28 Sandoz Ag Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds
CA2017383A1 (en) 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
WO1992009285A1 (en) 1990-11-27 1992-06-11 The Procter & Gamble Company Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections
US5149704A (en) * 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
CA2197364A1 (en) 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
WO1999000121A1 (en) * 1997-06-26 1999-01-07 Eli Lilly And Company Antithrombotic agents
US6372759B1 (en) * 1997-06-26 2002-04-16 Eli Lilly And Company Antithrombotic agents
JP2000080085A (ja) * 1997-09-01 2000-03-21 Kyorin Pharmaceut Co Ltd ６，７−非対称ジ置換キノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法
WO2000050387A1 (en) 1999-02-22 2000-08-31 Pacific Corporation Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof
PL350357A1 (en) 1999-03-12 2002-12-02 Boehringer Ingelheim Pharma Heterocyclic urea and related compounds useful as anti−inflammatory agents
WO2001028987A1 (en) * 1999-10-15 2001-04-26 Du Pont Pharmaceuticals Company Benzylcycloalkyl amines as modulators of chemokine receptor activity
AU8066701A (en) 2000-07-20 2002-02-05 Neurogen Corp Capsaicin receptor ligands
JP2004506714A (ja) 2000-08-21 2004-03-04 パシフィック　コーポレーション 新規チオ尿素化合物及びこれを含有する薬学的組成物
KR100453080B1 (ko) 2000-08-21 2004-10-15 주식회사 태평양 신규 티오카르밤산 유도체 및 이를 함유하는 약제학적조성물
KR100564902B1 (ko) 2000-08-21 2006-03-30 주식회사 태평양 신규 티오우레아 유도체 및 이를 함유하는 약제학적 조성물
JP2002080073A (ja) 2000-09-07 2002-03-19 Kyokuto Kobunshi Kk 電子レンジ用自動開孔袋
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
PE20030417A1 (es) * 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
IL165871A0 (en) * 2002-06-27 2006-01-15 Schering Ag Substituted quinoline CCR5 receptor antagonists
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229808D0 (en) 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
CA2563494A1 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Urea derivatives as antagonists of the vanilloid receptor (vr1)

Also Published As

Publication number Publication date
UY27446A1 (es) 2003-04-30
WO2003022809A3 (en) 2003-07-17
ATE420083T1 (de) 2009-01-15
US8063078B2 (en) 2011-11-22
JP4463552B2 (ja) 2010-05-19
AR038786A1 (es) 2005-01-26
AP1818A (en) 2008-01-07
EP1425277B1 (en) 2009-01-07
HUP0401923A3 (en) 2012-09-28
MA26216A1 (fr) 2004-07-01
CN1247568C (zh) 2006-03-29
EP1425277B8 (en) 2009-04-01
BR0212468A (pt) 2004-10-19
SI1425277T1 (sl) 2009-04-30
JP2010100632A (ja) 2010-05-06
JP2005504074A (ja) 2005-02-10
DE60230773D1 (de) 2009-02-26
AU2002329397B2 (en) 2006-04-27
OA12659A (en) 2006-06-19
NZ531137A (en) 2006-08-31
EP2036902A3 (en) 2009-05-06
NO20085077L (no) 2004-06-04
EA007731B1 (ru) 2006-12-29
NO327009B1 (no) 2009-04-06
PL213639B1 (pl) 2013-04-30
EP1425277A2 (en) 2004-06-09
KR100955967B1 (ko) 2010-05-04
MY138086A (en) 2009-04-30
KR20040041610A (ko) 2004-05-17
IL160755A (en) 2009-09-01
TWI283665B (en) 2007-07-11
PT1425277E (pt) 2009-03-05
US20090163506A1 (en) 2009-06-25
KR101063679B1 (ko) 2011-09-07
AP2004002982A0 (en) 2004-03-31
CA2458632C (en) 2011-08-23
PE20030417A1 (es) 2003-08-06
MXPA04002379A (es) 2004-05-31
IL160755A0 (en) 2004-08-31
KR20100082390A (ko) 2010-07-16
WO2003022809A2 (en) 2003-03-20
PL369026A1 (en) 2005-04-18
HK1066534A1 (en) 2005-03-24
EP2298757A3 (en) 2011-12-28
KR20090026369A (ko) 2009-03-12
CN1553905A (zh) 2004-12-08
HUP0401923A2 (hu) 2005-01-28
ES2316607T3 (es) 2009-04-16
DK1425277T3 (da) 2009-03-16
CY1109449T1 (el) 2014-08-13
EP2036902A2 (en) 2009-03-18
NO20085078L (no) 2004-06-04
CA2458632A1 (en) 2003-03-20
EA200400432A1 (ru) 2004-12-30
EP2298757A2 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
NO20040014L (no) Nye forbindelser
NO20041003L (no) Nye forbindelser
NO20034665L (no) Nye forbindelser
NO20035428D0 (no) Nye anti-ineffektiver
NO20034992D0 (no) Nye 4-aninlinokinolin-3-karboksamider
NO20026064L (no) Nye forbindelser
NO20023933L (no) Nye forbindelser
NO20044588L (no) Nye forbindelser
NO20044432L (no) Nye forbindelser
DK1671949T3 (da) Substituerede pyridinylaminer
NO20034308D0 (no) Nye tyrokinase-inhibitorer
NO20055219D0 (no) Nye forbindelser
NO20034970D0 (no) Nye arylheteroalkylaminderivater
DE60219284D1 (de) Dreischichtige maschenware
NO20025151D0 (no) Nye forbindelser
DE50206892D1 (de) Substituierte imidazotriazinone
NO20034773L (no) Nye ftalazinoner
NO20031141D0 (no) Nye forbindelser
NO20034695D0 (no) Nye sammensetninger
NO20040066L (no) Nye antikonvulsivaderivater
NO20014597D0 (no) Fremgangsmåte
NO20026162D0 (no) Nye forbindelser
NO20041185L (no) Nye sykloheksylsulfoner
IS2523B (is) Turn vindorkuvers
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees